These medicines include semaglutide (marketed as Ozempic for diabetes and Wegovy for weight management), liraglutide (Victoza for diabetes and Saxenda for weight management), dulaglutide (Trulicity, for diabetes only), and tirzepatide (Mounjaro for diabetes, Zepbound for weight management), which combines GLP-1 action with glucose-dependent insulinotropic polypeptide (GIP) receptor agonism
Federal guidance allows states broad discretion in coverage decisions
If Thrive GLP-1 reduces hunger from 8/10 to 5/10 even without dramatic weight loss, it is providing value through improved dietary adherence
Adequate levels can prevent nerve damage, which helps improve coordination and reduce tingling sensations
Acetylation of PAX7 controls muscle stem cell self-renewal and differentiation potential in mice
It is currently approved for type 2 diabetes control as well as reducing the risk of cardiovascular events in T2D patients